XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

Executive Summary

• XORTX Therapeutics entered into a securities purchase agreement for a registered direct offering of 1,746,631 common shares at US $0.63 per share.
• The offering is expected to generate gross proceeds of approximately US $1.1 million, with closing anticipated on or about October 22, 2025.
• Net proceeds will be used for working capital and general corporate purposes.

Key Details

• Offering Size: 1,746,631 common shares (or equivalents).
• Purchase Price: US $0.63 per share.
• Gross Proceeds: Approximately US $1.1 million before placement agent fees and other expenses.
• Closing Date: Expected on or about October 22, 2025, subject to customary conditions and TSX Venture Exchange approval.
• Use of Proceeds: Working capital and general corporate purposes.
• Placement Agent: D. Boral Capital LLC (sole placement agent).
• Securities Registration: Issuance under an effective shelf registration statement on Form F‑3 (File No. 333-269429) declared effective by the SEC on February 3, 2023.
• Prospectus Supplement: To be filed with the SEC; will be available on the SEC website and from D. Boral Capital LLC upon request.

Notable Quotes

(No direct quotes were provided in the release.)